Article and Video CATEGORIES
Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.
For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer.
Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
For this series, the doctors review cases related to KRAS positive non small cell lung cancer.
In this video, the panel discussion is regarding a 71 year old female with KRAS positive non small cell lung cancer with an underlying autoimmune condition of scleroderma.
We thank AstraZeneca Merck Genentech Takeda and Lilly for their support!
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…